551-03-002 / 551-03-002 ISMRM Abstract

Type 2 Diabetes in Older Adults is Associated with Increased Blood Brain Barrier Permeability and Reduced Cognitive Function

Primary: Neuro - Aging

Secondary: Neuro - Alzheimer's Disease

551-03-002 · Advanced MRI Biomarkers of Brain Aging, Vascular Health, and Alzheimer’s Disease · Wednesday, 13 May, 4:00 PM–5:36 PM · Power Pitch Theatre 1

Keywords: Diabetes Treatment Alzheimer's Disease Cognition Blood brain barrier

Accepted

Anujit Saha^1,2, Wen Shi³, Mohamad N Elsharydah², Jeffrey Schaffert⁴, Jack R Kaufman⁴, Jennine Leary², Alison Jin², Jaime Almandoz², Hanzhang Lu³, Binu Thomas ^1,2

¹University of Texas at Dallas, Richardson, United States of America

²University of Texas Southwestern Medical Center, Dallas, United States of America

³Johns Hopkins University School of Medicine, Baltimore, United States of America

⁴Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, United States of America

Presenting Author: Binu Thomas

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591-604. doi: 10.1038/s41574-018-0048-7. PubMed PMID: 30022099; PubMed Central PMCID: PMC6397437. [doi] [pmid]

2. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-46. Epub 20200730. doi: 10.1016/S0140-6736(20)30367-6. PubMed PMID: 32738937; PubMed Central PMCID: PMC7392084. [doi] [pmid]

3. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-38. Epub 2011/11/04. doi: 10.1038/nrn3114. PubMed PMID: 22048062; PubMed Central PMCID: PMC4036520. [doi] [pmid]

4. Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018;21(10):1318-31. Epub 20180924. doi: 10.1038/s41593-018-0234-x. PubMed PMID: 30250261; PubMed Central PMCID: PMC6198802. [doi] [pmid]

5. Lin Z, Li Y, Su P, Mao D, Wei Z, Pillai JJ, et al. Non-contrast MR imaging of blood-brain barrier permeability to water. Magn Reson Med. 2018;80(4):1507-20. Epub 2018/03/03. doi: 10.1002/mrm.27141. PubMed PMID: 29498097; PubMed Central PMCID: PMC6097906. [doi] [pmid]

6. Lin Z, Sur S, Liu P, Li Y, Jiang D, Hou X, et al. Blood-Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease. Ann Neurol. 2021;90(2):227-38. Epub 2021/05/28. doi: 10.1002/ana.26134. PubMed PMID: 34041783; PubMed Central PMCID: PMC8805295. [doi] [pmid]

7. Lin Z, Jiang D, Liu D, Li Y, Uh J, Hou X, et al. Noncontrast assessment of blood-brain barrier permeability to water: Shorter acquisition, test-retest reproducibility, and comparison with contrast-based method. Magn Reson Med. 2021;86(1):143-56. Epub 2021/02/10. doi: 10.1002/mrm.28687. PubMed PMID: 33559214; PubMed Central PMCID: PMC8466682. [doi] [pmid]

8. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6. Epub 2021 Jun 27. Erratum in: Lancet. 2021 Jul 17;398(10296):212. doi: 10.1016/S0140-6736(21)01556-7. PMID: 34186022. [doi] [pmid]

9. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647. [doi] [pmid]

10. Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. PMID: 34370970. [doi] [pmid]

11. Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. PMID: 34672967. [doi] [pmid]

12. Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID: PMC8826179. [doi] [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/551-03-002